Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its...
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21...
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026...
At VivaTech 2026, Taiwan-Based MaiAgent Says Enterprises Should Stop Building RAG and AI Agent Systems From Scratch
TAIPEI and PARIS, June 19, 2026 /PRNewswire/ -- At VivaTech 2026, MaiAgent, a Taiwan-based enterprise AI agent platform, said it is helping enterprises worldwide advance their AI transformation by moving AI agents from proof of concept to production...
Cohesity Secures Earliest Invented Patent in the Industry for GenAI Retrieval-Augmented Generation (RAG) Platform Built on Secondary Data
Patent validates Cohesity's architectural lead in applying GenAI to secondary data to unlock AI without data movement SINGAPORE, June 3, 2026 /PRNewswire/ -- Cohesity, a leader in AI-powered data security, today announced that the U.S. Patent and...
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now...
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products...
F5 2026 Solution Day Kicks Off in Hong Kong, Leading the Way in AI and Multicloud Era with Digital Resilience
HONG KONG, March 18, 2026 /PRNewswire/ -- On March 18, 2026, F5 hosted its 2026 Solution Day in Hong Kong, centered on the theme, "Digital Resilience in the AI and Multicloud Era." As cloud and SaaS failures reach a critical inflection point, the...
WhaleFlux Signals a Shift Toward Architecting Enterprise AI Systems as Enterprise AI Enters a New Phase in 2026
SAN FRANCISCO, Jan. 21, 2026 /PRNewswire/ -- As enterprise AI adoption moves beyond experimentation and into production, the industry is entering a new phase where system reliability, governance, and long-term operability matter more than model...
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral...